
FDA approves LYTENAVA™, first ophthalmic bevacizumab for wet AMD, offering 12 years exclusivity in $8.5B US retina market
Outlook Therapeutics announced FDA approval of LYTENAVA™ (bevacizumab-vikg), the first and only FDA-approved ophthalmic bevacizumab for treating wet age-related macular degeneration (AMD). This approval provides retina specialists and patients with a...


